Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2016/1467583 http://scihub22266oqcxt.onion/10.1155/2016/1467583 C4808526!4808526!27034879     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Case+Rep+Rheumatol 2016 ; 2016 (ä): ä Nephropedia Template TP {{tp|p=27034879|t=2016. Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |pdf=|usr=}}{{27034879}} gab.com Text Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease JO: Case Rep Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27034879 #FOAvip Reports have shown that antitumor necrosis factor alpha (anti-TNF-?) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-? agents under clinical remission. A 31-year-old patient with vasculo-BD was initially treated with a high dose of steroid and intravenous cyclophosphamide therapy. Six months later, however, the disease recurred. IFX was administered and immediately the disease activity was reduced. Fortunately, we could discontinue IFX after 18-month remission and no recurrence has been observed. Based on previous reports and our patient, all patients who could discontinue IFX sustained clinical remission for at least one year, continued taking immunosuppressive agents such as methotrexate and azathioprine, and had vascular involvements only in non-life-threatening major vessels such as leg or arm arteries/veins. This is a report suggesting the possibility of discontinuation of IFX in vasculo-BD. Twit Text FOAVip Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease ????Case Rep Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27034879 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27034879 #FOAvip English Wikipedia <ref>{{Cite pmid|27034879}}</ref> Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease #MMPMID27034879 Nakamura A; Miyamura T; Suematsu E Case Rep Rheumatol 2016[]; 2016 (ä): ä PMID27034879show ga Reports have shown that antitumor necrosis factor alpha (anti-TNF-?) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-? agents under clinical remission. A 31-year-old patient with vasculo-BD was initially treated with a high dose of steroid and intravenous cyclophosphamide therapy. Six months later, however, the disease recurred. IFX was administered and immediately the disease activity was reduced. Fortunately, we could discontinue IFX after 18-month remission and no recurrence has been observed. Based on previous reports and our patient, all patients who could discontinue IFX sustained clinical remission for at least one year, continued taking immunosuppressive agents such as methotrexate and azathioprine, and had vascular involvements only in non-life-threatening major vessels such as leg or arm arteries/veins. This is a report suggesting the possibility of discontinuation of IFX in vasculo-BD. äSuccessful Discontinuation of Infliximab in a Refractory Case of Vascu(epmc).pdf DeepDyve Pubget Overpricing